UPDATED Apr 23, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$745.69 | -0.7% | 98.2% | US$671.7b | US$813.32 | PE128.2x | E27.2% | 0.7% | Pharmaceuticals & Biotech | ||
UNH | US$486.18 | 1.5% | 0.7% | US$447.3b | US$568.86 | PE29.1x | E19.7% | 1.5% | Healthcare | ||
JNJ | US$149.56 | 3.3% | -8.0% | US$360.4b | US$173.60 | PE18.8x | E5.1% | 3.3% | Pharmaceuticals & Biotech | ||
MRK | US$126.88 | 1.2% | 11.9% | US$321.4b | US$137.58 | PE880.5x | E25.9% | 2.4% | Pharmaceuticals & Biotech | ||
ABBV | US$169.54 | 3.2% | 4.8% | US$300.2b | US$184.14 | PE62.3x | E23.4% | 3.7% | Pharmaceuticals & Biotech | ||
TMO | US$574.59 | 5.0% | 7.8% | US$219.3b | US$611.21 | PE36.6x | E11.1% | 0.3% | Pharmaceuticals & Biotech | ||
AZN | UK£112.68 | 3.7% | -4.9% | UK£174.7b | UK£129.63 | PE36.5x | E16.3% | 2.0% | Pharmaceuticals & Biotech | ||
DHR | US$253.11 | 5.7% | 8.9% | US$187.5b | US$267.79 | PE46.1x | E13.5% | 0.4% | Pharmaceuticals & Biotech | ||
ABT | US$107.59 | 1.6% | -1.1% | US$186.7b | US$126.33 | PE33.3x | E11.3% | 2.0% | Healthcare | ||
PFE | US$26.32 | 3.5% | -31.9% | US$149.0b | US$31.62 | PE69.8x | E22.3% | 6.4% | Pharmaceuticals & Biotech | ||
AMGN | US$273.54 | 3.6% | 14.5% | US$146.7b | US$300.27 | PE21.8x | E8.9% | 3.3% | Pharmaceuticals & Biotech | ||
ISRG | US$377.08 | 0.8% | 27.8% | US$133.8b | US$419.63 | PE67.3x | E11.5% | n/a | Healthcare | ||
SYK | US$334.91 | -0.3% | 12.1% | US$127.4b | US$365.69 | PE40.2x | E12.7% | 1.0% | Healthcare | ||
ELV | US$532.92 | 4.7% | 17.8% | US$123.9b | US$598.95 | PE19.8x | E12.5% | 1.2% | Healthcare | ||
MDT | US$81.29 | 2.8% | -9.6% | US$107.9b | US$94.75 | PE25.7x | E10.3% | 3.4% | Healthcare | ||
VRTX | US$404.91 | 3.0% | 25.2% | US$104.7b | US$460.34 | PE28.9x | E11.5% | n/a | Pharmaceuticals & Biotech | ||
BSX | US$68.99 | 1.5% | 35.0% | US$101.4b | US$73.40 | PE64.6x | E18.0% | n/a | Healthcare | ||
CI | US$352.65 | 1.9% | 42.1% | US$100.0b | US$381.44 | PE19.4x | E9.6% | 1.6% | Healthcare | ||
BMY | US$48.99 | 2.4% | -28.0% | US$99.3b | US$56.20 | PE12.4x | E9.9% | 4.9% | Pharmaceuticals & Biotech | ||
REGN | US$907.32 | 0.7% | 16.6% | US$97.5b | US$1,035.68 | PE24.7x | E10.9% | n/a | Pharmaceuticals & Biotech | ||
CSL | AU$278.45 | 2.1% | -8.9% | AU$134.6b | AU$306.81 | PE35.4x | E14.7% | 1.3% | Pharmaceuticals & Biotech | ||
CVS | US$68.50 | -0.1% | -5.2% | US$86.3b | US$88.42 | PE10.3x | E7.1% | 3.9% | Healthcare | ||
HCA | US$319.43 | 2.7% | 14.9% | US$84.5b | US$341.19 | PE16.1x | E6.4% | 0.8% | Healthcare | ||
GSK | UK£16.51 | 3.8% | 14.5% | UK£67.5b | UK£20.06 | PE13.7x | E9.3% | 3.5% | Pharmaceuticals & Biotech |